You have full access to this article via your institution. Our conclusions are the following: (i) plerixafor ‘on demand’ was efficient in most of the lymphoma patients who had a low PB CD34+ cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback